1. Home
  2. CCCC vs VNDA Comparison

CCCC vs VNDA Comparison

Compare CCCC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

SELL

Current Price

$3.06

Market Cap

350.6M

Sector

Health Care

ML Signal

SELL

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

SELL

Current Price

$4.54

Market Cap

301.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CCCC
VNDA
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
350.6M
301.1M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
CCCC
VNDA
Price
$3.06
$4.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
★ $12.86
$11.75
AVG Volume (30 Days)
★ 2.0M
819.7K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 16.45
N/A
EPS
★ N/A
N/A
Revenue
$35,947,000.00
★ $216,105,000.00
Revenue This Year
N/A
$15.16
Revenue Next Year
N/A
$35.50
P/E Ratio
★ N/A
N/A
Revenue Growth
1.02
★ 8.72
52 Week Low
$1.69
$4.27
52 Week High
$5.17
$9.91

Technical Indicators

Market Signals
Indicator
CCCC
VNDA
Relative Strength Index (RSI) 44.23 33.34
Support Level $2.88 $4.45
Resistance Level $3.20 $5.37
Average True Range (ATR) 0.22 0.17
MACD 0.02 -0.03
Stochastic Oscillator 54.54 20.41

Price Performance

Historical Comparison
CCCC
VNDA

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: